Anastrozole

Overview

Anastrozole is a third-generation non-steroidal aromatase inhibitor developed by AstraZeneca and marketed under the brand name Arimidex. It belongs to the triazole class of compounds and acts as a potent, selective, and reversible inhibitor of the aromatase enzyme (CYP19A1). Anastrozole was first approved by the FDA in 1995 for the treatment of advanced breast cancer in postmenopausal women and has since become one of the most widely prescribed aromatase inhibitors worldwide.

Unlike steroidal aromatase inhibitors such as exemestane, anastrozole does not possess structural similarity to androgens and does not form a permanent covalent bond with the enzyme. Instead, it binds competitively and reversibly to the heme group within the aromatase active site through coordination of its triazole nitrogen with the iron atom. This reversible binding means that aromatase activity can recover relatively quickly upon discontinuation of the drug, with estrogen levels typically returning to baseline within 2-3 weeks.

At the standard clinical dose of 1 mg daily, anastrozole suppresses circulating estradiol levels by approximately 80-90% in postmenopausal women. The drug has excellent oral bioavailability and a terminal elimination half-life of approximately 40-50 hours, supporting once-daily dosing. Anastrozole is primarily metabolized through N-dealkylation, hydroxylation, and glucuronidation, with the majority of the dose excreted renally.

Mechanism of Action

Anastrozole inhibits the aromatase enzyme through competitive, reversible binding to the enzyme’s active site. Aromatase catalyzes the rate-limiting step in estrogen biosynthesis: the conversion of androstenedione to estrone and testosterone to estradiol. By blocking this conversion, anastrozole effectively reduces circulating estrogen levels throughout the body.

Triazole-Heme Coordination

The mechanism of inhibition involves the coordination of the triazole nitrogen in anastrozole with the iron atom of the heme prosthetic group at the active site of CYP19A1. This coordination displaces the oxygen molecule normally bound to the heme iron, preventing the oxidative reactions necessary for aromatization of the A-ring of the androgen substrate. The two nitrile-substituted benzyl groups flanking the triazole ring provide hydrophobic interactions with residues in the substrate-binding pocket, conferring high selectivity for aromatase over other cytochrome P450 enzymes.

Selectivity Profile

Anastrozole demonstrates high selectivity for aromatase relative to other steroidogenic cytochrome P450 enzymes. At therapeutic concentrations, it does not significantly affect the biosynthesis of cortisol, aldosterone, or other adrenal steroids. This selectivity is clinically important because earlier-generation aromatase inhibitors such as aminoglutethimide lacked this selectivity and caused adrenal insufficiency requiring glucocorticoid replacement. Studies have confirmed that anastrozole at doses up to 10 mg daily does not affect basal or ACTH-stimulated cortisol or aldosterone levels.

Estrogen Suppression Dynamics

Following oral administration, anastrozole achieves steady-state plasma concentrations within approximately 7 days of daily dosing. At steady state, the drug produces approximately 80-90% suppression of plasma estradiol, estrone, and estrone sulfate. The degree of estrogen suppression is dose-dependent up to 1 mg, with minimal additional suppression at higher doses, establishing 1 mg as the optimal clinical dose.

Research Summary

Anastrozole has been evaluated in several landmark clinical trials that established aromatase inhibitors as the standard of care in hormone receptor-positive breast cancer treatment.

ATAC Trial

The Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial, first reported in The Lancet (2002), was a pivotal Phase III study that randomized 9,366 postmenopausal women with early-stage hormone receptor-positive breast cancer to receive anastrozole, tamoxifen, or the combination as adjuvant therapy for 5 years. The trial demonstrated that anastrozole significantly improved disease-free survival compared to tamoxifen (HR 0.87, 95% CI 0.78-0.97, p=0.01), with a 26% reduction in contralateral breast cancer risk. Anastrozole was also associated with fewer thromboembolic events and endometrial cancers but more musculoskeletal complaints and fractures compared to tamoxifen. The combination arm showed no advantage over tamoxifen alone and was discontinued.

Dose Optimization and Pharmacokinetics

Buzdar et al. (2006) published comprehensive pharmacokinetic analyses demonstrating the dose-response relationship of anastrozole. These studies established that 1 mg daily provides near-maximal aromatase inhibition and confirmed the drug’s favorable pharmacokinetic profile, including high oral bioavailability, linear pharmacokinetics, and minimal drug-drug interactions mediated through CYP450 enzymes. The terminal elimination half-life of 40-50 hours supports steady-state maintenance with once-daily dosing.

Bone Health Considerations

Long-term follow-up of aromatase inhibitor trials has identified bone mineral density loss as a significant clinical concern. The profound estrogen suppression achieved by anastrozole accelerates bone resorption, resulting in approximately 2-4% loss of bone mineral density per year during treatment. This has led to clinical guidelines recommending baseline and periodic bone density monitoring for patients receiving aromatase inhibitor therapy, with bisphosphonate or denosumab co-administration when clinically indicated.

Dosing in Published Research

Anastrozole is an FDA-approved prescription medicine, sold as Arimidex. According to the FDA-approved labeling, the dose across its breast-cancer indications in postmenopausal women is one 1 mg tablet taken once daily, with treatment in the advanced-disease setting continued until tumor progression. These figures are drawn from FDA-approved prescribing information.

Safety and Side Effects

Anastrozole is an FDA-approved drug with a well-characterized safety profile. Common adverse effects include hot flashes, joint and muscle pain (which can be substantial and is a frequent reason for discontinuation), fatigue, mood changes, and headache. Its most clinically significant long-term effect follows from estrogen suppression: anastrozole reduces bone mineral density and increases the risk of osteoporosis and fractures, and bone health is monitored during treatment. It can adversely affect the lipid profile, and a higher rate of ischemic cardiovascular events has been reported in some comparative data. Anastrozole is contraindicated in pregnancy because of the risk of fetal harm, and it has no role in premenopausal women without ovarian suppression.

Current Research Status

Anastrozole is an FDA-approved prescription medication, marketed as Arimidex, approved for the treatment of hormone-receptor-positive breast cancer in postmenopausal women. Use outside that setting, including off-label use to control estrogen in men using anabolic steroids, is not an approved indication and is not supported by the approval. As a prescription drug it should be used under medical supervision.

Frequently Asked Questions